T he optimal initial strategy for controlling disease in patients with rheumatoid arthritis (RA) remains elusive. Although the benefits of early treatment with disease modifying antirheumatic drugs (DMARDs) are indisputable, [1] [2] [3] [4] [5] [6] [7] [8] the order in which to use the various DMARDs and whether to use them singly or in combination is less certain. The traditional approach has been to use sequential DMARD monotherapy with substitution of an alternative DMARD when there is inadequate response or toxicity to the first DMARD, but long term studies have indicated several drawbacks with this strategy. [9] [10] [11] [12] Induction of sustained remission is seldom achieved. Individual DMARDs tend to be ineffective in a proportion of patients or lose their effectiveness with time. Only 5-15% of patients with RA maintain the initial response to a DMARD, with the exception of methotrexate and prednisolone, beyond 5 years. Also, prior DMARD use and longer duration of disease affect the likelihood of response to DMARD treatment, and subsequent DMARDs therefore tend not to be as effective as the first. 2 Although disease progression is retarded to some extent with this approach, structural damage and functional decline progress while the ''right'' drug is sought. Thus, in recent years, there has been increased interest in using combination DMARD therapy for patients with early RA.
PRINCIPLES BEHIND COMBINATION DMARD THERAPY
The principle behind combination therapy is to combine drugs with different mechanisms of action to increase efficacy, while maintaining a favourable side effect/toxicity profile, analogous to the use of combination cytotoxic treatment in oncology. Different strategies in the use of combination therapy have individual merits and disadvantages. In the step-down approach, the most aggressive treatment is offered at a stage when the patient is likely to be most responsive to pharmacological measures. Once the disease is brought under control, the drugs with the least favourable toxicity profile are sequentially withdrawn and treatment is maintained with the agent with the best efficacy/ toxicity trade off. In the step-up approach, aggressive treatment is advocated only for a subset of patients not responding to monotherapy. Administration of multiple DMARDs can therefore be avoided in patients who would otherwise have responded well to a single agent. This approach also makes it easier to identify the offending agent when a new adverse event occurs.
LESSONS LEARNT FROM EXISTING COMBINATION STUDIES
Several lessons have been learnt from combination trials in general, and those performed in early RA in particular:
N Combination therapy improves clinical response, delays radiographic progression, improves functional outcome, and reduces work disability compared with monotherapy. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] N A step-down strategy may be better than a step-up strategy as it offers the best chance for rapid and effective suppression of inflammation.
There is limited evidence from the BeSt trial 18 that patients with DMARD naive early ''established'' RA receiving ''step-down'' combination therapy, initially with either methotrexate, sulfasalazine, and prednisolone or methotrexate and infliximab have a better clinical response and radiological outcome than those who receive ''sequential monotherapy'' or step-up therapy.
N Corticosteroids and anti-tumour necrosis factor (TNF) drugs offer an attractive option as part of combination therapy for patients with early RA as they can rapidly suppress rheumatoid inflammation. 13 15 17 26 N Even short term use of aggressive combination therapy during the ''early established'' phase of RA, results in long term benefits compared with monotherapy.
The COBRA trial reported that patients who received early aggressive step-down combination therapy with methotrexate, sulfasalazine, and prednisolone for ,6 months had less radiographic progression at 5 years than those who received sulfasalazine monotherapy.
14 Five year results from the Fin-RA Co trial also reported reduced radiographic progression 20 and reduced work disability 21 among patients who received combination therapy with methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone for the first 2 years compared with those who received sequential monotherapy. Treatment with infliximab and methotrexate has been shown to halt radiographic progression at 2 years compared with methotrexate monotherapy.
17
N Combinations so far proved to be effective have mostly included corticosteroids or anti-TNF agents. [13] [14] [15] [16] [17] [18] [19] [20] [21] Methotrexate has been the ''anchor'' drug in all successful combination trials.
Among the combinations that did not include either corticosteroids or anti-TNF, triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine 23 and step-up therapy with methotrexate, sulfasalazine, and ciclosporin 22 have been shown to be effective. Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine has also been shown to be effective in two separate studies among patients with established RA. 27 28 N Although it was previously thought that combination therapy was more toxic, 29 more recent large, well designed randomised controlled trials have shown that this may not be true.
Despite these positive results, the available evidence is still insufficient to recommend use of combination DMARD therapy for all patients with early RA. The gaps in existing knowledge on combination treatment in early RA are mainly due to several shortcomings in existing combination studies. These shortcomings are discussed in the rest of this article and future research directions are suggested.
GAPS IN CURRENT KNOWLEDGE AND DIRECTIONS FOR FUTURE RESEARCH
Timing of treatment All ''early RA'' combination trials have based their definition of early RA on duration of symptoms (maximum symptom duration of up to 3 years), and recruited only those patients who met American College of Rheumatology (ACR) criteria for RA. 30 The ACR criteria were developed only to separate patients with established RA from those with other musculoskeletal conditions, and do not perform well in early disease. 31 Moreover, most patients recruited to early RA combination trials had plain radiographic evidence of erosive changes at baseline. Thus, currently available evidence on combination therapy in early RA only relates to patients with early ''established'' RA.
There are several reasons why it would be useful to study the role of combination therapy in patients with ''very early'' RA. Firstly, several studies have shown that early DMARD treatment in RA leads to better medium and long term clinical, radiological, and functional outcome 5 6 32-34 and that a delay of even as little as 8-9 months can result in detrimental long term outcome. 35 36 Longitudinal observational data from the Norfolk Arthritis Register (NOAR) have shown that radiological and functional disability outcome in patients who receive a DMARD within 6 months of symptom onset is similar to that of patients who do not need treatment with a DMARD. 5 6 A recent study reported that 60% of patients who started DMARD treatment after a median disease duration of 3 months achieved an ACR50 response at 3 years compared with 25% of those who started DMARD treatment after a median disease duration of 12 months. 8 Although our belief that the biology of the disease may be fundamentally altered by starting DMARD treatment during the very early phase of RA before the disease becomes persistent has not been substantiated through well designed randomised controlled trials, the sooner the DMARD is started the better.
Secondly, as discussed above, there is evidence that even short term use of aggressive combination therapy during the early established phase results in long term benefits (reduced radiographic progression and improved work disability) compared with monotherapy. 14 17 20 21 Thirdly, although the benefits of early intervention have been established without doubt, none of the early or very early RA trials have reported significant remission. This is far from ideal, especially as the focus in recent years has shifted from simply controlling disease manifestations or retarding disease progression to complete suppression of synovitis and total prevention of damage. In other words, we should aim for complete remission and no longer be satisfied with an ACR20 or ACR50 response. It follows that there is an urgent need to study the role of combination therapy among patients with very early RA on the basis of available data favouring (very) early over delayed introduction of DMARD therapy, and data suggesting long term benefits with short term use of combination DMARD therapy during the early established phase of RA.
''Complete remission of RA should be our aim and combination treatment should be tested among patients with very early RA'' How do we select patients with ''very early'' RA? Among various factors that predict persistence (or in other words, progression to RA) among patients with early, undifferentiated inflammatory arthritis, symptom duration lasting more than 12 weeks, presence of rheumatoid factor, or anti-cyclic citrullinated peptide antibody and radiographic erosions seem to be the most important. [37] [38] [39] [40] Thus, future trials should also include patients with persistent polyarthritis lasting more than 12 weeks (provided that other specific causes such as postviral arthritis have been excluded) as treatment of such patients with a DMARD is started in practice. 41 Prediction models for self limiting, persistent erosive and persistent non-erosive disease have been developed, but they require further validation. 40 Optimal initial strategy Although the benefits of combination therapy are emerging, we still do not know if it is appropriate for all patients with early RA. It is unclear if it would be better to use blanket treatment with a combination of drugs in all patients or whether the use of aggressive treatment should be restricted to patients with suboptimal response to monotherapy.
''The efficacy of various strategies should be tested among patients with early RA to identify the optimal initial strategy'' For example, although the combination of infliximab and methotrexate has been shown to better than methotrexate monotherapy, 17 it is not known if it is best to use this combination in all patients with early RA at the outset or whether anti-TNF drugs should only be added for patients with suboptimal response to methotrexate. None of the existing trials (with the exception of the BeSt trial 18 ) have compared the different strategies, and most of the current evidence on combination therapy in early RA relates to trials that compared different combinations of disease modifying drugs with monotherapy. Although trials to test the various possible combinations are needed to identify the ones with the best efficacy/toxicity trade off, it is more important to test the efficacy of various strategies to identify the optimal initial strategy.
As discussed above, corticosteroids or anti-TNF drugs are likely to be included as part of a step-down strategy as they offer the best chance for rapid and effective suppression of inflammation. However, long term use of corticosteroids is inappropriate in view of their side effects. Worries about long term safety and lack of cost effectiveness would also preclude indefinite use of anti-TNF agents. Thus, even if combination therapy were to be used as the initial treatment in all patients, optimal maintenance regimens are currently unknown. Methotrexate might be a good choice as it has a higher long term retention than other disease modifying drugs. 42 Also, limited evidence suggests that methotrexate may be better than ciclosporin as a maintenance agent. 43 
Choice of individual drugs in the combination
Several gaps remain about the optimum choice of individual components in the combination. Firstly, we now know that step-down regimens should probably include corticosteroids or anti-TNF agents as they offer the best chance of remission, but it is not known which of those two would offer the best results. Thus, a trial comparing induction treatment with these two agents would be useful. Secondly, the optimal dose of corticosteroids to be used is also not known as both low 15 and high doses 13 of corticosteroids have been shown to retard radiographic progression. Thirdly, it is unclear if the different strategies would work best with a certain combination of drugs. Fourthly, although leflunomide and methotrexate have been shown to be equally efficacious, 44 leflunomide has never been studied among patients with early RA. Finally, earlier combination trials did not use DMARDs in adequate doses, possibly for fear of inducing side effects. For example, a modest 7.5 mg/week of MTX was used in the COBRA trial, and it was discontinued very early (after week 28) in all patients. 13 Although more recent trials have pushed the dose of individual drugs in the combination to the maximum recommended, parenteral methotrexate, which has a bioavailability of 100%, has never been tested. 45 ''Advances in pharmacogenetics should help in the choice of DMARDs for combination therapy''
The choice of individual drugs in the combination has been empirical and partly extrapolated from combination studies in established RA. The usefulness of most DMARDs in RA was discovered by chance, and their mechanisms of action are not fully understood. 46 It is therefore difficult to make a completely rational decision when choosing individual drugs for the combination. As far as possible, drugs are combined based on current knowledge of mechanisms of action, pharmacokinetics, efficacy, and toxicity. 47 Thus, combining methotrexate and leflunomide may be synergistic as the former inhibits purine metabolism, while the latter inhibits pyrimidine metabolism. Both methotrexate and azathioprine inhibit purine metabolic pathways, and hence may not be a rational combination. Other combinations such as methotrexate and ciclosporin might be synergistic in view of a positive pharmacokinetic interaction (ciclosporin reduces renal excretion of methotrexate). Recent advances in understanding the pharmacogenetics of disease modifying drugs may pave the way for more rational combinations in future. 48 The ''tight control of rheumatoid arthritis'' (TICORA) study took a different approach and demonstrated that using conventional agents more effectively may be more important than the actual drug chosen. 49 Routine outpatient management was compared with an intensive strategy comprising regular objective assessments of disease activity for protocoldriven escalation of conventional treatment among patients with early RA. The remission rates were impressive: 65% v 16% for intensive v standard care, respectively. It is of course possible that some of this benefit might have resulted from the greater use of combinations of DMARDs and corticosteroids in the intensively treated group.
Tailoring of treatment
Although it is currently not known if different therapeutic strategies should be tailored according to prognosis, there is some evidence to suggest that combination therapy is appropriate for patients with early RA with poor prognostic factors. In a recent double blind trial, it was demonstrated that patients with early established RA with poor prognosis according to the Persistent Inflammatory Symmetrical Arthritis (PISA) scoring system, treated with infliximab and methotrexate combination therapy, had less radiographic progression at 1 year than those who were treated with methotrexate alone. The benefits were sustained at 2 years despite withdrawal of infliximab. 50 In the COBRA trial, patients who received sulfasalazine monotherapy had more radiographic progression if they were positive for shared epitope than if they were negative for shared epitope. However, radiographic progression was similar among patients who received combination therapy irrespective of their shared epitope status. 51 This might possibly be due to better responsiveness to combination therapy of patients who were shared epitope positive. The influence of shared epitope status on responsiveness to combination therapy has also been demonstrated among patients with late RA. 52 Several factors have been proposed as bad prognostic factors in RA: high erythrocyte sedimentation rate or C reactive protein, presence and titre of rheumatoid factor and anti-cyclic citrullinated peptide antibody at baseline, the HLA-DRB1*04 shared epitope allele (especially homozygotic), and early radiographic erosions. 53 Prediction models that combine these factors have been developed, but have not been validated. A properly validated prediction model that could easily be used at the bedside and which would differentiate those patients with a benign outcome from those with a severe outcome is currently unavailable. The immediate need, therefore, is to develop and validate such a prediction model to stratify patients according to prognosis. This should then lead to studies to find out whether the most aggressive treatment should be targeted at patients who are likely to have a worse long term outcome.
Trial design
Trial design has been deficient in several trials. In general, the most conclusive evidence is derived from double blind, randomised controlled trials, but most existing early RA combination trials are open or single blind studies. There are some reasons why this strategy may not always be practical. In the trial by Proudman et al, in which patients with early RA were randomised to receive either aggressive combination therapy with methotrexate, ciclosporin, and intra-articular corticosteroids into all inflamed joints or sulfasalazine monotherapy, 54 it might have been unethical to inject placebos into all inflamed joints. Also, double blinding is difficult when different strategies are compared, and when different routes (oral, subcutaneous, intravenous, etc) are employed to administer drugs. But on the whole, it would be unacceptable not to perform double blind studies while investigating a common disease such as RA.
Although there is a paucity of data on step-up treatment in early RA, several step-up trials have been performed among patients with late established RA. Most trials have studied patients with suboptimal response to methotrexate, and addition of leflunomide, 55 ciclosporin, 56 anti-TNF drugs, 57 and triple therapy (sulfasalazine and hydroxychloroquine) 58 has been shown to be beneficial compared with addition of placebo. A disadvantage of this design is that trial patients have already had a suboptimal response to one drug, and if combination therapy is shown to be beneficial, one can never be sure if the better response was due to the combination or whether it was solely due to the second drug that was added. 59 Moreover, it might be unethical to add placebo to a drug to which the patient had had a suboptimal response. Thus, step-up trials should be designed such that if patients with suboptimal response to MTX are studied, they should be randomised to receive either MTX plus ''active drug'' or placebo plus ''active drug''.
Earlier trials mostly used fixed dose protocols, and the decision to change or intensify DMARD treatment was not driven by disease activity. For example, in the COBRA trial, 13 prednisolone and methotrexate were both tapered after weeks 28 and 40, respectively, in all patients, irrespective of disease activity. Moreover, prednisolone was used at a fixed dose of 60 mg/day (tapering to 7.5 mg/day over 6 weeks) in all patients and not tailored according to disease activity. However, insight is changing over time and more recent trials have used protocols driven by disease activity.
CONCLUSION
Although combination therapy has been shown to be more effective than monotherapy, and to have no additional short term adverse events, there are several questions (table 1) that need to be answered through randomised controlled trials of adequate power. Current evidence on combination therapy is limited to patients with early established RA, and hence there is an urgent need to test various treatment strategies among patients with very early RA. As aggressive combination therapy (or even single drug therapy) is inappropriate for patients whose arthritis is likely to remit, a properly validated prediction model that could predict persistence among patients with early undifferentiated inflammatory arthritis would be helpful. RA is a chronic disease with a course measured in decades, and effective regimens to sustain therapeutic benefit over the longer term are needed. The optimal use of corticosteroids and anti-TNF drugs, and the role of leflunomide in early RA need to be defined. Finally, it is important to validate prognostic markers, and to determine if therapeutic strategies need to be tailored according to prognosis. Only with such further information will we know the optimal initial strategy for patients with early RA or RAlike polyarthritis. 
